NCT05274893Unknown1 期
A Randomized, Open-label, Two-cycle Crossover Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 28
- 主要终点
- Cmax
研究概览
简要总结
This is a multi-center, open-label, pharmacokinetic comparison study of SYHX2011 and Abraxane® in patients with advanced breast cancers after single IV infusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Voluntarily sign the written informed consent.
- •Female patients aged 18 to 75 years (inclusive).
- •Histologically and/or cytologically diagnosed advanced breast cancer.
- •Patients who are receiving paclitaxel for injection (albumin bound) monotherapy or who, in the judgement of the investigator, may benefit from monotherapy with the trial formulation.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Expected survival time ≥3 months.
- •The results of hematological, renal, and hepatic function are within the following ranges:
- •White blood cell count (WBC) ≥3.0 × 10^9/L; Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L; Platelet count (PLT)≥ 100 × 10^9/L; Hemoglobin (Hb) ≥ 90 g/L; Prothrombin time (PT)/activated partial thrombin time (APTT) ≤1.5 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; AST、ALT ≤ 2.5 × ULN (≤5 × ULN in patients with liver metastasis); Serum creatinine ≤ 1.5 × ULN.
- •Patients have no pregnancy plan within 6 months after entering the study, voluntarily take effective contraceptive measures, and have no egg donation plan.
- •Fully understand the purpose and requirements of this trial, and can complete the whole trial process according to the test requirements.
排除标准
- •Have severe allergy to paclitaxel drugs or human serum albumin, or history of significant hypersensitivity or idiosyncratic reaction.
- •Patients with serious medical conditions are considered unsuitable for inclusion by the investigator.
- •Patients who have undergone major surgery within 3 months prior to screening or planned to have major surgery during the study period.
- •Have a history of alcohol, drug abuse or drug addiction.
- •Patients who are pregnant or breasting.
- •Patients with one or more positive tests for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), human immunodeficiency virus (HIV) or treponema pallidum antibody.
- •Received anti-tumor therapy such as radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, chemotherapy [paclitaxel for injection (albumin bound) monotherapy less than 21 days] within 4 weeks prior to study dosing or participated in other clinical trials within the 5 half-lives of the treated drug, whichever is longer. According to the determination of the investigator, the washout period can be appropriately shortened or extended. If there are interfering monoclonal antibodies that require an appropriate extension of the washout period when necessary, or if other antitumor drugs need to be combined during the study.
- •Obvious abnormality in ECG examination, QTc interval > 470 ms at baseline.
- •Peripheral neuropathy ≥ grade
- •Blood donation or massive blood loss (> 400 mL) within 90 days before screening.
- •Use of drugs with high protein binding rate, or CYP2C8 inhibitors, or CYP3A4 inhibitors, within 1 week before enrollment.
- •Ingestion of a specific diet (e.g., grapefruit) within 48 hours prior to the administration of the study drug, capable of affecting the absorption, distribution, metabolism, and excretion of the drug.
- •Toxicity due to antitumor drug use before enrollment did not recover to ≤ grade 1 or baseline, except for alopecia.
- •Not suitable for this study as judged by the investigator for any other reason.
研究组 & 干预措施
SYHX2011(T)-Abraxane®(R)
Experimental
Patients will be administrated with SYHX2011 followed by Abraxane®
干预措施: SYHX2011 and Abraxane® (Drug)
Abraxane®(R)-SYHX2011(T)
Experimental
Patients will be administrated with Abraxane® followed by SYHX2011
干预措施: SYHX2011 and Abraxane® (Drug)
结局指标
主要结局
Cmax
时间窗: From time zero up to 72 hours post-dose
Maximum plasma concentration
AUC0-t
时间窗: From time zero up to 72 hours post-dose
Area under the plasma concentration time curve from time zero to the last measurable concentration
AUC0-∞
时间窗: From time zero up to 72 hours post-dose
Area under the plasma concentration-time curve from time zero to infinity
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
An Open-label, Randomized, 2-Period, Crossover, Pharmacokinetics StudyPregnancy PreventionNCT05360576Lupin Research Inc40
已完成
1 期
Clinical Trial to Investigate the Efficacy and Safety of DWJ1351HealthyNCT03753477Daewoong Pharmaceutical Co. LTD.64
已完成
1 期
Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed ConditionsIdiopathic Pulmonary FibrosisNCT06589921Overseas Pharmaceuticals, Ltd.24
已完成
1 期
Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed ConditionsIdiopathic Pulmonary FibrosisNCT06588517Overseas Pharmaceuticals, Ltd.12
已完成
1 期
Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-NS250 and IY-NT-SRPharmacokineticsPharmacodynamicsNCT06725992Il-Yang Pharm. Co., Ltd.56